<DOC>
	<DOCNO>NCT02808104</DOCNO>
	<brief_summary>The purpose study determine whether controlled release formulation mazindol effective placebo treatment Attention Hyperactivity Disorder ( ADHD ) adult .</brief_summary>
	<brief_title>Mazindol Controlled Release Adults With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This study outpatient , randomize , double-blind , placebo-controlled trial adult subject ADHD randomize either oral mazindol control release placebo daily . Subjects treat study medication placebo 6 week visit occur weekly measure efficacy adverse event adjustment medication dose necessary .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Mazindol</mesh_term>
	<criteria>Subject primary diagnosis ADHD establish comprehensive psychiatric evaluation base DSM5 criterion . Subject function appropriate level intellectually judged investigator . Subject minimum baseline score 28 screen baseline use ADHDRSDSM5 Subject minimum score 4 ( moderate ) CGIS screen . Women childbearing potential must nonpregnant , nonlactating , agree acceptable method contraception . Acceptable method contraception include intrauterine device ( IUDs ) , hormonal contraceptive ( oral , depot , patch injectable ) , double barrier method condom diaphragms spermicidal gel foam . In good general physical health determine medical history , baseline physical examination , vital sign , clinical laboratory test electrocardiogram ( ECG ) measurement . Subject fluent write spoken English willing able sign write informed consent prior receipt study medication begin study procedure . Subject willing able follow instruction , comply protocol requirement make require study visit . Any primary DSM5 Axis I disorder ADHD comorbid DSM5 disorder currently require treatment . Lifetime history DSM5 bipolar disorder Treatment medication psychiatric neurologic condition ( e.g. , amphetamine , MPH product , antidepressant , antipsychotic , mood stabilizer , antiepileptic ) pressor agent concurrently within 14 day randomization . Concurrent medical illness would interfere conduct study opinion investigator . History significant cardiovascular disease , structural cardiac abnormality , cardiomyopathy , heart failure , serious heart rhythm abnormality , coronary heart disease , transient ischemic attack stroke , serious cardiac problem . Family history sudden cardiac death . Clinically significant ECG abnormality QTc ( Bazett correction ) interval &gt; 450 msec . Resting sit systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 90 mm Hg . BMI &lt; 18 &gt; 40 kg/m2 . Other medication CNS effect cognition attention ( e.g. , sedate antihistamine decongestant ) . Positive drug screen ( UDS ) screening ( exception current ADHD medication ) . Concomitant use sensitive CYPA4/5 CYP2D6 substrates narrow therapeutic index . Pregnant lactating . Ongoing psychotherapeutic treatment treatment ADHD begin less three month entry study . Recent current DSM5 Substance Use Disorder moderate great severity ( i.e. , &gt; 4 SUD symptom ) , exclude nicotine . Suicidal ideation within past 3 month , suicidal behavior within past year , CSSRS score 3 , 4 5 ideation item . Evidence outofrange laboratory value screen review , approve document clinically significant Study Investigator . A history significant drug allergy systemic allergic disease ( e.g. , urticaria , atopic dermatitis ) , known/suspected hypersensitivity form mazindol . Any condition clinically significant abnormal finding physical examination , medical history , clinical laboratory result screen , opinion Study Investigator , would make subject unsuitable study put additional risk . Treatment investigational drug within 30 day precede first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>